NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Oxford Drug Design

Oxford Drug Design

Private
OxfordHealthcare & Life Scienceshttps://oxforddrugdesign.com/

Last Round

Crowdfunding

Mar 4, 2026

Est. Valuation

$15.17M

Total Funding Raised

$8.29M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Oxford Drug Design is a biotechnology company that discovers and develops novel therapeutics for cancer and other diseases using a proprietary AI and machine learning platform with a core expertise in aminoacyl-tRNA synthetase (aaRS) enzymes.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Infrastructure

Keywords

computational drug discoverygenerative AIAI drug discoverysmall-molecule designvirtual screeningligand designstructural biologyin silico drug discoveryoncology therapeuticsantibiotic discoverytRNA synthetasedrug discovery platformAI biotechhit-to-leadmolecular modeling

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oxford Drug Design Comps

Public and private peers based on sector, stage, and business model.

Oxford Drug Design comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Oxford Drug Design Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingMar 4, 2026
GrantFeb 20, 2025
GrantSep 26, 2024
GrantMay 22, 2024
DebtMay 19, 2022
VC Round
Nov 5, 2019

Key People

Founding team and executive leadership

Alan D. Roth

Chief Executive Officer

Executive Team

Oxford Drug Design Investors

Notable investors and investment history

Oxford Drug Design investors
InvestorRounds
ACF InvestorsVC Round, Debt
PACE (Pathways to Antimicrobial Clinical Efficacy)Grant
CARB-XGrant
IP GroupVC Round
o2h venturesVC Round, Debt
DHSCVC Round, Grant
Meltwind AdvisoryDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors increased 5825% MoM, from 24 to 1.4K.

  • Feb 20, 2025

    $1.34M grant received from PACE

Oxford Drug Design Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oxford Drug Design Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oxford Drug Design's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range12
Year Founded2001
Last FundingMar 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.